Compare · BBNX vs DXCM
BBNX vs DXCM
Side-by-side comparison of Beta Bionics Inc. (BBNX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.50B, about 50.2x BBNX ($467.9M).
- Over the past year, BBNX is down 29.8% and DXCM is down 28.6% - DXCM leads by 1.2 points.
- DXCM has been more active in the news (9 items in the past 4 weeks vs 4 for BBNX).
- DXCM has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- DexCom Inc.
- Price
- $10.49-0.80%
- $60.93+0.99%
- Market cap
- $467.9M
- $23.50B
- 1M return
- +7.04%
- -7.44%
- 1Y return
- -29.79%
- -28.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2005
- News (4w)
- 4
- 9
- Recent ratings
- 16
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BBNX
- Beta Bionics to Present at the Bank of America Securities Health Care Conference
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- SEC Form DEFA14A filed by Beta Bionics Inc.
- SEC Form DEF 14A filed by Beta Bionics Inc.
- Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
- Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
Latest DXCM
- Dexcom to Host Investor Day on May 14, 2026
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time